Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776072 · ClinicalTrials.gov registry record
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 2,978
- Enrollment target
NCT02776072: Completed study, sponsored by Biogen.
NCT02776072 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 2,978 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02776072 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 2,978 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF). Secondary objectives of the study are: To evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with DMF, glatiramer acetate (GA), teriflunomide, or fingolimod both in the overall participant cohort and in a subset of participants who were naïve to disease-modifying therapy (DMT) and were diagnosed with multiple sclerosis (MS) within 3 years of starting the index therapy; To compare relapse activity, defined as annualized relapse rate (ARR), among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare MS-related hospitalizations among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare intravenous corticosteroid use among participants treated with DMF, GA, teriflunomide, or fingolimod.
Primary Outcome
Single time point per participant retrospective medical record abstraction with no required study visits or procedures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,978 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-12 |
What the finished NCT02776072 record still lists
NCT02776072 is an observational study that tracks outcomes without assigning an intervention. Its 2,978 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02776072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02776072 about?
NCT02776072 is a clinical study titled "Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)". The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF). Secondary objectives of the study are: To evaluate the real-world clinical effectivenes...
What is the current status of trial NCT02776072?
This trial is currently completed. The enrollment target is 2,978 participants. The study started on 2016-05. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT02776072?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia